论文部分内容阅读
目的观察前列腺素E1(PGE1)对亚急性乙型重型肝炎治疗的临床疗效。方法 63例亚急性乙型重型肝炎患者随机均分为治疗组(33例)和对照组(30例)。两组采用甘草酸二铵(甘利欣)、促肝细胞生长素、门冬氨酸钾镁、多种维生素、人血白蛋白、血浆等常规治疗;治疗组加用PGE1注射液10μg,每日1次。疗程均为4周。检测治疗前和疗程结束后的血直接胆红素、总胆红素、丙氨酸氨基转移酶/谷氨酸氨基转移酶。结果两组治疗后肝功能均有明显改善;治疗组血清总胆红素明显低于对照组[(64.3±25.4)μmol/L vs.(82.4±35.2)μmol/L](P<0.05)。治疗组有效率明显高于对照组(81.8%vs.70.0%)(P<0.05)。结论加用PGE1能明显改善亚急性乙型重型肝炎的治疗效果。
Objective To observe the clinical efficacy of prostaglandin E1 (PGE1) in the treatment of sub-acute type B severe hepatitis. Methods Sixty-three patients with subacute type B severe hepatitis were randomly divided into treatment group (n = 33) and control group (n = 30). Two groups were treated with diammonium glycyrrhizinate (Glycyrrhizin), hepatocyte growth-promoting hormone, potassium-magnesium aspartate, multiple vitamins, human serum albumin and plasma. The treatment group was treated with PGE1 injection 10μg daily 1 time. The course of treatment is 4 weeks. Blood direct bilirubin, total bilirubin and alanine aminotransferase / glutamate aminotransferase were measured before treatment and after treatment. Results The liver function of the two groups was significantly improved after treatment. The serum total bilirubin in the treatment group was significantly lower than that in the control group [(64.3 ± 25.4) μmol / L vs. (82.4 ± 35.2) μmol / L] (P <0.05). The effective rate of the treatment group was significantly higher than that of the control group (81.8% vs. 70.0%) (P <0.05). Conclusion Addition of PGE1 can significantly improve the therapeutic effect of subacute B hepatitis.